As at July 23, 2021Show prices
SaskWorks Diversified (Class A - Series A) 21.2782
SaskWorks Diversified (Class A - Series F) 24.0790
SaskWorks Resources (Class R - Series A) 11.5971
SaskWorks Resources (Class R - Series F) 12.4625
Brent Zettl, President and CEO, CanniMed Therapeutics Inc.(TSX:CMED) and Rob Duguid , Chief Investment Officer, PFM Capital Inc. joined Brady Fletcher, Managing Director, TSX Venture Exchange to open the market. CanniMed is a Canadian-based, international plant biopharmaceutical company with 15 years of pharmaceutical cannabis cultivation experience. The Company has a plant biotechnology research and product development program focused on the production of plant-based materials for pharmaceutical, agricultural and environmental applications. CanniMedTherapeutics Inc., will commence trading on Toronto Stock Exchange on December 29, 2016. For more information, please visit www.cannimed.ca
